The Epstein–Barr virus (EBV) glycoproteins H (gH) and L (gL) form a heterodimer essential for viral entry into host cells. This complex mediates membrane fusion in cooperation with other viral glycoproteins, enabling EBV to infect both B lymphocytes and epithelial cells. Antibodies targeting gH/gL can block this fusion process, thereby neutralizing infection. Such antibodies are valuable tools for studying EBV pathogenesis, evaluating vaccine candidates, and developing diagnostic assays. Because gH/gL are conserved and exposed on the viral envelope, they elicit strong immune responses, making anti‑gH/gL antibodies important in both research and potential therapeutic applications.